GlassScriptPhysician profile
Anwar Chowdhury
NPI 1427111715
$8,441.01
in general payments reported to CMS, 2019-2025
17 companies · $3,096 in 2025
The $3,096 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.17 · 2022: $262 · 2023: $2,779 · 2024: $2,231 · 2025: $3,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,057 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,056.64 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,801.10 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,418.43 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $797.90 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $776.10 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $750.64 | 2023-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $530.92 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $456.74 | 2023-2025 | Spravato, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $385.23 | 2024-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $378.84 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $330.67 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $211.51 | 2023-2025 | Rexulti |
| Tris Pharma INC | $166.05 | 2024-2025 | Dyanavel Xr |
| Corium, LLC | $136.80 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $100.85 | 2023 | Quviviq |
| Bausch Health US, LLC | $82.94 | 2022-2023 | Aplenzin, Wellbutrin |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $63.60 | 2024-2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.69 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwar Chowdhury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.